Targeted Degradation of Extracellular Secreted and Membrane Proteins

Overview

Journal Trends Pharmacol Sci

Specialty Pharmacology

Date 2023 Sep 27

PMID 37758536

Authors

Xuankun Chen

Yaxian Zhou

Yuan Zhao

Weiping Tang

Affiliations

Soon will be listed here.

Abstract

Targeted protein degradation (TPD) involving chimeric molecules has emerged as one of the most promising therapeutic modalities in recent years. Among various reported TPD strategies, proteolysis-targeting chimeras (PROTACs) stand out as a significant breakthrough in small-molecule drug discovery and have garnered the most attention to date. However, PROTACs are mainly capable of depleting intracellular proteins. Given that many important therapeutic targets such as cytokines, growth factors, and numerous receptors are membrane proteins or secreted extracellularly, there is interest in the development of novel strategies to degrade these protein categories. We review advances in this emerging area and provide insights to enhance the development of novel TPDs targeting extracellular proteins.

Citing Articles

A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy.

Xiao Y, He Z, Li W, Chen D, Niu X, Yang X Nat Commun. 2025; 16(1):1388.

PMID: 39910101 PMC: 11799215. DOI: 10.1038/s41467-025-56648-6.

Lysosome-targeting chimeras containing an endocytic signaling motif trigger endocytosis and lysosomal degradation of cell-surface proteins.

Fang T, Zheng Z, Li N, Zhang Y, Ma J, Yun C Chem Sci. 2024; .

PMID: 39391383 PMC: 11459673. DOI: 10.1039/d4sc05093b.

Development of folate receptor targeting chimeras for cancer selective degradation of extracellular proteins.

Zhou Y, Li C, Chen X, Zhao Y, Liao Y, Huang P Nat Commun. 2024; 15(1):8695.

PMID: 39379374 PMC: 11461649. DOI: 10.1038/s41467-024-52685-9.

The application of nanodiscs in membrane protein drug discovery & development and drug delivery.

Dong Y, Tang H, Dai H, Zhao H, Wang J Front Chem. 2024; 12:1444801.

PMID: 39359422 PMC: 11445163. DOI: 10.3389/fchem.2024.1444801.

Development of Integrin Targeting Chimeras (ITACs) for the Lysosomal Degradation of Extracellular Proteins.

Zhou Y, Liao Y, Zhao Y, Tang W ChemMedChem. 2024; 19(24):e202300643.

PMID: 39245642 PMC: 11649485. DOI: 10.1002/cmdc.202300643.

References

Lai A, Crews C . Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2016; 16(2):101-114. PMC: 5684876. DOI: 10.1038/nrd.2016.211. View

Rosenberg S, Shanahan F, Yamazoe S, Kschonsak M, Zeng Y, Lee J . Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation. Cell Chem Biol. 2023; . DOI: 10.1016/j.chembiol.2023.01.007. View

Stevens C, Zhou Y, Teng P, Rault L, Liao Y, Tang W . Development of Oligomeric Mannose-6-phosphonate Conjugates for Targeted Protein Degradation. ACS Med Chem Lett. 2023; 14(6):719-726. PMC: 10258825. DOI: 10.1021/acsmedchemlett.2c00479. View

Sun R, Meng Z, Lee H, Offringa R, Niehrs C . ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation. Cell Chem Biol. 2023; 30(7):739-752.e8. DOI: 10.1016/j.chembiol.2023.05.010. View

Wu Y, Lin B, Lu Y, Li L, Deng K, Zhang S . Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins. Angew Chem Int Ed Engl. 2023; 62(15):e202218106. DOI: 10.1002/anie.202218106. View

Douglass Jr E, Miller C, Sparer G, Shapiro H, Spiegel D . A comprehensive mathematical model for three-body binding equilibria. J Am Chem Soc. 2013; 135(16):6092-9. PMC: 3717292. DOI: 10.1021/ja311795d. View

Liu Z, Yu D, Song H, Postings M, Scott P, Wang Z . Enantioselective Degrader for Elimination of Extracellular Aggregation-Prone Proteins hIAPP Associated with Type 2 Diabetes. ACS Nano. 2023; 17(9):8141-8152. DOI: 10.1021/acsnano.2c11476. View

Ren C, Sun N, Liu H, Kong Y, Sun R, Qiu X . Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. J Med Chem. 2021; 64(13):9152-9165. DOI: 10.1021/acs.jmedchem.1c00373. View

Glazier D, Liao J, Roberts B, Li X, Yang K, Stevens C . Chemical Synthesis and Biological Application of Modified Oligonucleotides. Bioconjug Chem. 2020; 31(5):1213-1233. DOI: 10.1021/acs.bioconjchem.0c00060. View

10.

Zhang H, Han Y, Yang Y, Lin F, Li K, Kong L . Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation. J Am Chem Soc. 2021; 143(40):16377-16382. DOI: 10.1021/jacs.1c08521. View

11.

Deshaies R . Multispecific drugs herald a new era of biopharmaceutical innovation. Nature. 2020; 580(7803):329-338. DOI: 10.1038/s41586-020-2168-1. View

12.

Aboelez M, Belal A, Xiang G, Ma X . Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR and EGFR. J Enzyme Inhib Med Chem. 2022; 37(1):1196-1211. PMC: 9067978. DOI: 10.1080/14756366.2022.2062338. View

13.

Bedford L, Lowe J, Dick L, Mayer R, Brownell J . Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2010; 10(1):29-46. PMC: 7097807. DOI: 10.1038/nrd3321. View

14.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

15.

Miao Y, Gao Q, Mao M, Zhang C, Yang L, Yang Y . Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes. Angew Chem Int Ed Engl. 2021; 60(20):11267-11271. DOI: 10.1002/anie.202102170. View

16.

Singh S, Streng-Ouwehand I, Litjens M, Weelij D, Garcia-Vallejo J, van Vliet S . Characterization of murine MGL1 and MGL2 C-type lectins: distinct glycan specificities and tumor binding properties. Mol Immunol. 2009; 46(6):1240-9. DOI: 10.1016/j.molimm.2008.11.021. View

17.

Ruffilli C, Roth S, Rodrigo M, Boyd H, Zelcer N, Moreau K . Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation. ACS Pharmacol Transl Sci. 2022; 5(10):849-858. PMC: 9578132. DOI: 10.1021/acsptsci.2c00142. View

18.

Yan G, Zhong X, Yue L, Pu C, Shan H, Lan S . Discovery of a PROTAC targeting ALK with in vivo activity. Eur J Med Chem. 2021; 212:113150. DOI: 10.1016/j.ejmech.2020.113150. View

19.

Cheng M, Yu X, Lu K, Xie L, Wang L, Meng F . Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. J Med Chem. 2020; 63(3):1216-1232. PMC: 7318554. DOI: 10.1021/acs.jmedchem.9b01566. View

20.

Cheng B, Ren Y, Cao H, Chen J . Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1. Eur J Med Chem. 2020; 199:112377. DOI: 10.1016/j.ejmech.2020.112377. View